Want to see AU:MEM full AI Analyst Report?
MEM Stock Chart & Stats
<AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EDT
<AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.01
Previous CloseN/A
Volume260.00K
Average Volume (3M)17.19M
Market Cap
AU$16.98M
Enterprise ValueAU$18.84
Total Cash (Recent Filing)AU$411.43K
Total Debt (Recent Filing)AU$4.63M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,087,233,600
10 Day Avg. Volume17,186,563
30 Day Avg. Volume17,186,563
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.50
Price to Sales (P/S)25.46
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe strong revenue growth indicates increasing demand for Memphasys's fertility technologies, suggesting successful market penetration and potential for future sales expansion.
Gross Profit MarginA high gross profit margin reflects efficient production and pricing strategies, which can support long-term profitability as the company scales its operations.
Innovative Product OfferingThe innovative Felix device positions Memphasys as a leader in reproductive technology, potentially driving competitive advantage and market share growth in the fertility sector.
Bears Say
Profitability ChallengesOngoing profitability issues may hinder Memphasys's ability to reinvest in growth and innovation, potentially impacting its long-term financial health and competitive position.
High Debt LevelsHigh leverage increases financial risk, limiting flexibility and potentially impacting the company's ability to finance future growth or weather economic downturns.
Cash Flow ChallengesNegative cash flows indicate operational inefficiencies and may constrain the company's ability to fund operations, invest in new projects, or manage debt obligations effectively.
Memphasys Ltd News
MEM FAQ
What was Memphasys Ltd’s price range in the past 12 months?
Memphasys Ltd lowest share price was <AU$0.01 and its highest was AU$0.01 in the past 12 months.
What is Memphasys Ltd’s market cap?
Memphasys Ltd’s market cap is AU$16.98M.
When is Memphasys Ltd’s upcoming earnings report date?
Memphasys Ltd’s upcoming earnings report date is Feb 19, 2027 which is in 174 days.
How were Memphasys Ltd’s earnings last quarter?
Currently, no data Available
Is Memphasys Ltd overvalued?
According to Wall Street analysts Memphasys Ltd’s price is currently Overvalued.
Does Memphasys Ltd pay dividends?
Memphasys Ltd does not currently pay dividends.
What is Memphasys Ltd’s EPS estimate?
Memphasys Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Memphasys Ltd have?
Memphasys Ltd has 3,087,233,600 shares outstanding.
What happened to Memphasys Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Memphasys Ltd?
Currently, no hedge funds are holding shares in AU:MEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Memphasys Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:MEM Sentiment 92%
Sector Average 61%
Sector Average 61%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.91%
Trailing 12-Months
Company Description
Memphasys Ltd
Memphasys Limited, an Australian enterprise, is dedicated to the development, manufacturing, and distribution of advanced cell and protein separation technologies, alongside associated consumable goods, for the healthcare, veterinary, and biotechnology sectors. Its leading innovation is Felix, an automated device engineered to swiftly and gently isolate high-quality sperm from raw semen samples, primarily for use in human in vitro fertilization (IVF) procedures. The company's product portfolio also includes ROSA, a rapid oxidative stress assay; the Samson Device, designed for quick equine pregnancy prediction; SemPort, a system for central laboratory human semen analysis from geographically dispersed donors; and AI-Port, an ambient temperature semen transport solution for animal artificial insemination. Incorporated in 2006, the company was formerly known as NuSep Holdings Limited until its rebranding to Memphasys Limited in July 2016, and is headquartered in Homebush, Australia.
Paragon Care Limited
―
Atomo Diagnostics Ltd.
―
Cryosite Limited
―
Genetic Signatures Ltd.
―
Monash IVF Group Ltd
―